Mavyret and Vosevi--two new combinations for chronic HCV infection

Med Lett Drugs Ther. 2017 Oct 9;59(1531):166-170.
No abstract available

MeSH terms

  • Aminoisobutyric Acids
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Carbamates / adverse effects
  • Carbamates / therapeutic use*
  • Cyclopropanes
  • Drug Combinations
  • Genotype
  • Hepacivirus / drug effects*
  • Hepacivirus / genetics
  • Hepacivirus / pathogenicity
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Heterocyclic Compounds, 4 or More Rings / adverse effects
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Humans
  • Lactams, Macrocyclic
  • Leucine / analogs & derivatives
  • Macrocyclic Compounds / adverse effects
  • Macrocyclic Compounds / therapeutic use*
  • Proline / analogs & derivatives
  • Pyrrolidines
  • Quinoxalines / adverse effects
  • Quinoxalines / therapeutic use*
  • Sofosbuvir / adverse effects
  • Sofosbuvir / therapeutic use*
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use*
  • Treatment Outcome

Substances

  • Aminoisobutyric Acids
  • Antiviral Agents
  • Benzimidazoles
  • Carbamates
  • Cyclopropanes
  • Drug Combinations
  • Heterocyclic Compounds, 4 or More Rings
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Pyrrolidines
  • Quinoxalines
  • Sulfonamides
  • voxilaprevir
  • pibrentasvir
  • Proline
  • Leucine
  • glecaprevir
  • velpatasvir
  • Sofosbuvir